Simulations Plus Inc., a global leader in model-informed and AI-accelerated drug development, recently hosted its 2026 Virtual Investor Day. During the event, the company highlighted its strategic direction and platform innovations, focusing on the evolution from a collection of best-in-class tools to an integrated, AI-enabled ecosystem supporting drug discovery, development, clinical operations, and commercialization. Company leaders emphasized the integration of cloud-enabled execution, reusable workflow patterns, and AI-assisted capabilities aimed at improving productivity and ensuring regulator-ready documentation. The event also underscored Simulations Plus’s commitment to aligning with FDA and EMA guidelines by using AI to augment, not replace, mechanistic modeling, ensuring outputs remain explainable and scientifically validated. A replay of the Investor Day broadcast is available on the Simulations Plus website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121307543) on January 21, 2026, and is solely responsible for the information contained therein.